AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

NYSE:PKIPerkinElmer Stock Price, Forecast & News

$101.47
-1.62 (-1.57 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$100.99
Now: $101.47
$103.46
50-Day Range
$91.30
MA: $98.43
$105.31
52-Week Range
$62.91
Now: $101.47
$105.70
Volume538,822 shs
Average Volume879,972 shs
Market Capitalization$11.30 billion
P/E Ratio50.23
Dividend Yield0.27%
Beta1.37
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More
PerkinElmer logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$6.21 per share
Book Value$25.33 per share

Profitability

Net Income$227.56 million

Miscellaneous

Employees13,000
Market Cap$11.30 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

PerkinElmer (NYSE:PKI) Frequently Asked Questions

How has PerkinElmer's stock been impacted by COVID-19 (Coronavirus)?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PKI stock has increased by 39.3% and is now trading at $101.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PerkinElmer?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 10 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PerkinElmer.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for PerkinElmer.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its earnings results on Tuesday, May, 5th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.54 by $0.13. The medical research company had revenue of $652.40 million for the quarter, compared to analyst estimates of $634.46 million. PerkinElmer had a return on equity of 16.52% and a net margin of 7.82%. The business's quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the business earned $0.69 earnings per share. View PerkinElmer's earnings history.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Thursday, April 30th. Investors of record on Friday, July 17th will be paid a dividend of $0.07 per share on Friday, August 7th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Thursday, July 16th. View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its second quarter earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of at least $0.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.59. The company issued revenue guidance of $610-720 million, compared to the consensus revenue estimate of $621.18 million.

What price target have analysts set for PKI?

15 brokerages have issued 12 month price targets for PerkinElmer's shares. Their forecasts range from $49.00 to $114.00. On average, they anticipate PerkinElmer's share price to reach $83.73 in the next year. This suggests that the stock has a possible downside of 17.5%. View analysts' price targets for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Media coverage about PKI stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PerkinElmer earned a news impact score of -2.4 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about PerkinElmer.

Are investors shorting PerkinElmer?

PerkinElmer saw a increase in short interest in June. As of June 15th, there was short interest totaling 2,790,000 shares, an increase of 13.4% from the May 31st total of 2,460,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is presently 2.8 days. Approximately 2.5% of the company's stock are short sold. View PerkinElmer's Current Options Chain.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), NVIDIA (NVDA), IBM (IBM), Visa (V), Alibaba Group (BABA), Home Depot (HD), Johnson & Johnson (JNJ), Pfizer (PFE), Thermo Fisher Scientific (TMO) and Adobe (ADBE).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Robecosam AG (0.42%), Envestnet Asset Management Inc. (0.04%), State of Alaska Department of Revenue (0.03%), Hudson Valley Investment Advisors Inc. ADV (0.02%), DNB Asset Management AS (0.01%) and Park National Corp OH (0.01%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View institutional ownership trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Robecosam AG, Park National Corp OH, and Private Trust Co. NA. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Pascale Witz, and Peter Barrett. View insider buying and selling activity for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Pure Financial Advisors Inc., IBM Retirement Fund, Rockland Trust Co., Envestnet Asset Management Inc., DNB Asset Management AS, Carroll Financial Associates Inc., and Hudson Valley Investment Advisors Inc. ADV. View insider buying and selling activity for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $101.47.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $11.30 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis. PerkinElmer employs 13,000 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.